Search results for "Cardioprotective Agent"

showing 5 items of 5 documents

C022 Experimental approaches of oxidative stress and cardiotoxicity associated with anthracyclines administration

2009

The chronic cardiotoxicity of anthracyclines anticancer drugs is one of the main factors which limits their prolonged use. Clinically, this cardiotoxicity results in a cardiomyopathy with irreversible congestive heart failure with high mortality. The molecular mechanisms, which could explain this cardiac toxicity, are complex but seem distinct from the anticancer mechanism. Several hypotheses were advanced, but it appears that the production of reactive oxygen and nitrogen species (RONS) constitutes the common denominator.In a first study, we evaluated the acute effect of epirubicin administration on the evolution of cardiac functional parameters and production of RONS. Isolated perfused ra…

CardiotoxicityChemotherapybusiness.industrymedicine.medical_treatmentCardiomyopathyGeneral MedicinePharmacologymedicine.diseasemedicine.disease_causeHeart failureAnesthesiamedicineDoxorubicinCardioprotective AgentCardiology and Cardiovascular MedicinebusinessOxidative stressmedicine.drugEpirubicinArchives of Cardiovascular Diseases
researchProduct

Cardioprotection and natural polyphenols: An update of clinical and experimental studies

2018

Myocardial ischemia is the leading cause of death worldwide. Despite better outcomes with early coronary artery reperfusion strategies, morbidity and mortality remain significant. The principal myocardial hallmark of myocardial ischemia is cell death and the associated impairment of cardiac contractility. In this way, the use of extracts from medicinal plants versus synthetic drugs to mitigate post-ischemic damage constitutes an alternative. Despite their proven beneficial effects in cardiovascular disorders, the use of many plants is questioned. Our aim is to update the clinical and experimental studies about the actions of medicinal plants and polyphenol-enriched extracts against ischemia…

0301 basic medicineCardiotonic AgentsMyocardial ischemiaCIENCIAS MÉDICAS Y DE LA SALUDMyocardial IschemiaMEDLINE030204 cardiovascular system & hematologyFisiologíaNATURAL PRODUCTS03 medical and health sciencesISCHEMIA-REPERFUSIONCARDIOPROTECTION0302 clinical medicineWeb of knowledgeMITOCHONDRIAAnimalsHumansMedicineCardioprotective AgentMedicinal plantsBeneficial effectsCause of deathCardioprotectionClinical Trials as TopicTraditional medicinePlant Extractsbusiness.industryPolyphenolsfood and beveragesGeneral MedicineMedicina Básica030104 developmental biologybusinessFood Science
researchProduct

HERS study disturbs hormonal replacement therapy

2000

Cardiovascular protection of hormonal replacement therapy was considered a fact. The effects of estrogens on lipid levels and vascular health gave biological support to estrogen cardioprotection. The recently published HERS study showing no protective effects of estrogen and progesterone replacement therapy on the risk of myocardial infarction or coronary deaths is provoking perplexity. These surprising results may have several causes such as the use of progesterone, the associated use of cardioprotective agents or the short observation period. However, the study results scope is rectricted to secondary prevention. These cannot be extrapolated to frequent conditions of postmenopausal women …

CardioprotectionSecondary preventionmedicine.medical_specialtyPostmenopausal womenbusiness.industrymedicine.drug_classPhysiologyGeneral Medicinemedicine.diseaseVascular healthEndocrinologyCardiovascular diseasesHormone replacement therapyEstrogenInternal medicinePrimary preventionmedicineCardioprotective AgentMyocardial infarctionpost-menopausalEstrogen replacement therapybusiness
researchProduct

Cardioprotective Effects of the Na + /H + Exchange Inhibitor Cariporide in Patients With Acute Anterior Myocardial Infarction Undergoing Direct PTCA

2000

Background —Activation of Na + /H + exchange in myocardial ischemia and/or reperfusion leads to calcium overload and myocardial injury. Experimental studies have shown that Na + /H + exchange inhibitors can attenuate Ca 2+ influx into cardiomyocytes. We therefore performed a multicenter, randomized, placebo-controlled clinical trial to test the hypothesis that inhibition of Na + /H + exchange limits infarct size and improves myocardial function in patients with acute anterior myocardial infarction (MI) treated with direct PTCA. Methods and Results —One hundred patients were randomized to receive placebo (n=51) or a 40-mg intravenous bolus of the Na + /H + exchange inhibitor cariporide (HOE…

AdultMalemedicine.medical_specialtySodium-Hydrogen Exchangersmedicine.medical_treatmentMyocardial InfarctionPlaceboGuanidinesVentricular Function LeftLesionchemistry.chemical_compoundPhysiology (medical)AngioplastyInternal medicinemedicineHumansCardioprotective AgentSulfonesMyocardial infarctionAngioplasty Balloon CoronaryAgedChemotherapybiologyCariporidebusiness.industryMyocardiumHeartMiddle Agedmedicine.diseaseTreatment OutcomechemistryAnesthesiabiology.proteinCardiologyFemaleCreatine kinasemedicine.symptomCardiology and Cardiovascular MedicinebusinessCirculation
researchProduct

Cardiovascular and Cardioprotective Agents in 2021

2021

Pharmacology2019-20 coronavirus outbreakCardiotonic AgentsCoronavirus disease 2019 (COVID-19)business.industrySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Cardiovascular AgentsPharmacologyCardiovascular SystemCardiovascular DiseasesDrug DiscoveryCardiovascular agentHumansMedicineCardioprotective AgentbusinessCurrent Pharmaceutical Design
researchProduct